GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SomnoMed Ltd (ASX:SOM) » Definitions » Total Liabilities

SomnoMed (ASX:SOM) Total Liabilities : A$34.02 Mil (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is SomnoMed Total Liabilities?

SomnoMed's Total Liabilities for the quarter that ended in Dec. 2023 was A$34.02 Mil.

SomnoMed's quarterly Total Liabilities increased from Dec. 2022 (A$39.63 Mil) to Jun. 2023 (A$40.09 Mil) but then declined from Jun. 2023 (A$40.09 Mil) to Dec. 2023 (A$34.02 Mil).

SomnoMed's annual Total Liabilities increased from Jun. 2021 (A$24.01 Mil) to Jun. 2022 (A$30.31 Mil) and increased from Jun. 2022 (A$30.31 Mil) to Jun. 2023 (A$40.09 Mil).


SomnoMed Total Liabilities Historical Data

The historical data trend for SomnoMed's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SomnoMed Total Liabilities Chart

SomnoMed Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.93 27.86 24.01 30.31 40.09

SomnoMed Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.14 30.31 39.63 40.09 34.02

SomnoMed Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

SomnoMed's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=18.36+(20.941+2.5535129566379E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.787)
=40.09

Total Liabilities=Total Assets (A: Jun. 2023 )-Total Equity (A: Jun. 2023 )
=62.491-22.403
=40.09

SomnoMed's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=17.459+(15.687+0.87
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=34.02

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=63.917-29.901
=34.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SomnoMed Total Liabilities Related Terms

Thank you for viewing the detailed overview of SomnoMed's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


SomnoMed (ASX:SOM) Business Description

Traded in Other Exchanges
Address
20 Clarke Street, Level 3, Crows Nest, Sydney, NSW, AUS, 2065
SomnoMed Ltd produces and sells oral treatment of sleep-related disorder devices. It manufactures and designs premium oral appliances for the treatment of sleep-disordered breathing relieving conditions. Its products include SomnoDent, Som Tabs, Som Morning Repositioner and others. Its geographical segments include North America, Europe, and Asia-Pacific. Business operations consist of the production and sale of products treating sleep-disordered breathing, which is the only reportable segment. Substantial revenue is realized from the European region.

SomnoMed (ASX:SOM) Headlines

No Headlines